Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Novo nordisk a::S save search
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
Published: 2022-07-10 (Crawled : 16:20) - globenewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
haemophilia phase 3
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
Published: 2022-04-29 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 5.98%
H: 1.44%
C: -0.42%
SNY | News | $46.385 2.19% 3M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: 11.11%
H: 3.67%
C: -4.33%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.53%
H: 2.37%
C: 0.26%
trial payment cancer phase 3
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | News | $144.345 -0.56% 330K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Investigational 2 mg Dose of Ozempic® (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic® 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial
Published: 2021-06-26 (Crawled : 04:20) - prnewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
diabetes blood injection phase 3 trial
Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
Published: 2021-06-26 (Crawled : 04:20) - globenewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
diabetes blood phase 3 trial
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
Published: 2021-04-21 (Crawled : 14:00) - globenewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.4%
H: 1.1%
C: 0.9%
obesity ev phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
ASNS | $0.828 21.75% 17.86% 18K
|
UONE | $2.36 19.8% 16.53% 75K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.